IBDEI160 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20835,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,20835,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,20835,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,20836,0)
 ;;=205.31^^118^1255^34
 ;;^UTILITY(U,$J,358.3,20836,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20836,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,20836,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,20836,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,20837,0)
 ;;=205.32^^118^1255^33
 ;;^UTILITY(U,$J,358.3,20837,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20837,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,20837,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,20837,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,20838,0)
 ;;=205.80^^118^1255^44
 ;;^UTILITY(U,$J,358.3,20838,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20838,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,20838,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,20838,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,20839,0)
 ;;=205.81^^118^1255^43
 ;;^UTILITY(U,$J,358.3,20839,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20839,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,20839,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,20839,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,20840,0)
 ;;=205.82^^118^1255^42
 ;;^UTILITY(U,$J,358.3,20840,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20840,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,20840,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,20840,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,20841,0)
 ;;=205.90^^118^1255^65
 ;;^UTILITY(U,$J,358.3,20841,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20841,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,20841,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,20841,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,20842,0)
 ;;=205.91^^118^1255^64
 ;;^UTILITY(U,$J,358.3,20842,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20842,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,20842,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,20842,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,20843,0)
 ;;=205.92^^118^1255^63
 ;;^UTILITY(U,$J,358.3,20843,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20843,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,20843,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20843,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,20844,0)
 ;;=206.00^^118^1255^6
 ;;^UTILITY(U,$J,358.3,20844,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20844,1,1,0)
 ;;=1^206.00
 ;;^UTILITY(U,$J,358.3,20844,1,8,0)
 ;;=8^Acute Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,20844,2)
 ;;=^336861
 ;;^UTILITY(U,$J,358.3,20845,0)
 ;;=206.01^^118^1255^5
 ;;^UTILITY(U,$J,358.3,20845,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20845,1,1,0)
 ;;=1^206.01
 ;;^UTILITY(U,$J,358.3,20845,1,8,0)
 ;;=8^Acute Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,20845,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,20846,0)
 ;;=206.02^^118^1255^4
 ;;^UTILITY(U,$J,358.3,20846,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20846,1,1,0)
 ;;=1^206.02
 ;;^UTILITY(U,$J,358.3,20846,1,8,0)
 ;;=8^Acute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20846,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,20847,0)
 ;;=206.10^^118^1255^15
 ;;^UTILITY(U,$J,358.3,20847,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20847,1,1,0)
 ;;=1^206.10
 ;;^UTILITY(U,$J,358.3,20847,1,8,0)
 ;;=8^Chr Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,20847,2)
 ;;=^336862
 ;;^UTILITY(U,$J,358.3,20848,0)
 ;;=206.11^^118^1255^14
 ;;^UTILITY(U,$J,358.3,20848,1,0)
 ;;=^358.31IA^8^2
